Libido News and Research

RSS

Libido in its common usage means sexual desire; however, more technical definitions, such as those found in the work of Carl Jung, are more general, referring to libido as the free creative—or psychic—energy an individual has to put toward personal development or individuation.

Teva, IVAX receive FDA approval for generic Lexapro to treat depression and GAD

The U.S. Food and Drug Administration today approved the first generic Lexapro (escitalopram tablets) to treat both depression and generalized anxiety disorder in adults.

27 Mar 2012

Only few OB-GYNs routinely inquire about patients' sexual issues

How often does your doctor ask about your sexual life? Unfortunately, the answer may be: not often enough. Leaving the subject off the check-up checklist could mean missing an important link to overall wellness.

23 Mar 2012

Watson commences Esmya Phase 3 trial in women with anemia linked to uterine leiomyomas

Watson Pharmaceuticals, Inc. today announced it has initiated its Phase 3 trial to evaluate the efficacy and safety of Esmya (ulipristal acetate) in women with anemia associated with uterine leiomyomas, a medical condition often referred to as uterine fibroids (myomas). Leiomyomata are benign solid tumors that often lead to excessive menstrual bleeding, anemia and pain, which ultimately may require surgical intervention.

12 Mar 2012

New clinical trial: Pycnogenol improves signs and symptoms of menopause

Half the population experiences menopause, and for those women, it is a condition they will experience for approximately one third of their lifetime. Alternative or natural remedies are an easy, effective way to improve signs and symptoms linked to the menopausal transition, without side effects.

7 Mar 2012

S1 submits Lorexys IND application for HSDD and Female Sexual Dysfunction treatment

S1 Pharmaceuticals, Inc. (S1) announced today that it has submitted its Investigational New Drug (IND) application to the U.S. Food and Drug Administration for Phase I-b clinical studies of SIP-104 (Lorexys). Lorexys is the Company's lead drug candidate for the treatment of Hypoactive Sexual Desire Disorder (HSDD) and Female Sexual Dysfunction (FSD).

21 Feb 2012

NTRR completes research and development of new erectile dysfunction treatment

With Neutra Corp.'s Pure Plus weight-loss supplement already in the midst of clinical trials, the company announced today that it has completed research and development of its next product in the Pure Plus line: an all-natural erectile dysfunction (ED) treatment.

13 Feb 2012

Sex declared safe for heart patients

A doctors’ group on Thursday suggested that sex may be safe for most heart patients. The American Heart Association added that having sex only slightly raises the chance for a heart attack. And that’s true for people with and without heart disease. Despite the higher risk for a heart patient to have a second attack, there’s no evidence that they have more sex-related heart attacks than people without cardiac disease. The updated advice was released online Thursday in the heart association journal, Circulation.

22 Jan 2012

Side effects and non-compliance with breast cancer therapy

Yet another study showed that more than a third of women taking a certain class of breast cancer drugs are so bothered by side effects that they stop taking the pills before their treatment is complete

12 Dec 2011

Many postmenopausal women quit breast cancer drugs early because of side effects

Why do so many postmenopausal women who are treated for estrogen-sensitive breast cancer quit using drugs that help prevent the disease from recurring? The first study to actually ask the women themselves -- as well as the largest, most scientifically rigorous study to examine the question -- reports 36 percent of women quit early because of the medications' side effects, which are more severe and widespread than previously known.

12 Dec 2011

FDA approves NDA for Edgemont's Fluoxetine 60 mg tablet

Edgemont Pharmaceuticals, LLC, a neuroscience focused company, today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Fluoxetine Tablets 60 mg.

12 Oct 2011

Fathers and family men low on testosterone: Study

A new study shows that men who spend time with their children have lower levels of testosterone than single guys. The study shows that family men experience a biological shift that may awaken their nurturing side.

13 Sep 2011

Even minor weight loss can improve men’s sex lives: Study

The team of Australian researchers placed 31 obese men with type 2 diabetes on either a meal replacement-based low-calorie diet or a low-fat, high-protein, reduced-carbohydrate diet meant to decrease calorie intake by 600 calories a day. A modest weight loss of 5 percent led to an easing of erectile dysfunction and improved sexual desire within eight weeks, and these improvements continued for 12 months, according to the study published Aug. 5 in The Journal of Sexual Medicine. Problems with urinary tract function also improved, the team added.

8 Aug 2011

Homosexual men with prostate cancer more likely to report problems with bicalutamide drug

Homosexual men taking bicalutamide for prostate cancer were much more likely to report sexual problems during treatment than heterosexual patients, according to a study in the July issue of the urology journal BJUI.

22 Jun 2011

GTx commences Capesaris Phase IIb trial in advanced prostate cancer

GTx, Inc., announced today that it initiated a Phase IIb clinical trial evaluating Capesaris, a selective estrogen receptor alpha agonist, compared to Lupron Depot for first line treatment of advanced prostate cancer.

20 Jun 2011

Age does not affect testosterone level in healthy older men

A decline in testosterone levels as men grow older is likely the result—not the cause—of deteriorating general health, say Australian scientists, whose new study finds that age, in itself, has no effect on testosterone level in healthy older men.

8 Jun 2011

Non-steroidal, oral contraceptive for men

Researchers at Columbia University Medical Center are honing in on the development of what may be the first non-steroidal, oral contraceptive for men. Tests of low doses of a compound that interferes with retinoic acid receptors (RARs), whose ligands are metabolites of dietary vitamin A, showed that it caused sterility in male mice.

7 Jun 2011

Cardiac resynchronization therapy improves sexual health in men with chronic heart failure

A new study published in the journal Clinical Cardiology reveals that in men with chronic heart failure, cardiac resynchronization therapy improves patients' libido, erectile dysfunction, and sexual performance.

2 Jun 2011

Sleep loss reduces healthy young man's testosterone levels

Cutting back on sleep drastically reduces a healthy young man's testosterone levels, according to a study published in the June 1 issue of the Journal of the American Medical Association.

1 Jun 2011

Watson launches Generess Fe low-dose oral contraceptives in the U.S.

Watson Pharmaceuticals, Inc., today announced the U.S. commercial launch of Generess Fe 0.8 mg/25 mcg, a new low-dose oral contraceptive option that's highly effective at preventing pregnancy and proven to provide users with short, lighter, predictable periods.

2 May 2011